Nanotraps for the containment and clearance of SARS-CoV-2



    • Inventors devised a nanomedicine termed “Nanotraps” that can completely capture and eliminate SARS-CoV-2 by triggering macrophages to engulf and clear the virus without becoming infected.
    • Ex vivo lung perfusion system. Zero toxicity was found in mice as evidenced by histological analysis of heart, liver, spleen, lung, and kidney, as well as blood chemistry and blood cell counts.
    • The Nanotraps have the potential to be formulated into a nasal spray or inhaler for easy administration and direct delivery to the respiratory system, as an oral or ocular liquid, or subcutaneous, intramuscular, or intravenous injection to target different sites of SARS-CoV-2 exposure, thus offering flexibility in administration and treatment.



    A) Scanning electron microscopy images of SARS-CoV-2 pseudovirus (cyan) captured by Nanotraps (orange). Scale bars: 300 nm. B) Neutralizing assay of pseudotyped SARS-CoV-2 infection of HEK293T-ACE2 cells comparing Nanotraps to soluble ACE2. C) Evaluation of pseudotyped SARS-CoV-2 infection of ex vivo lung perfusion system with live human lungs. D) Neutralizing assay of authentic SARS-CoV-2 infection of Vero E6 cells comparing Nanotraps to neutralizing antibody.




    • 10 times more effective than soluble ACE2 or neutralizing antibody counterparts
    • Stable after lyophilization at -20C for six months
    • Could be aerosolized for drug delivery via nasal spray


    • Therapeutics
    • Preliminary toxicology studies



    Reference ID

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.